Skip to content
ApprovedFDA approved

Finasteride (Propecia / Proscar)

Prescription hair loss and prostate drug that lowers levels of the hormone DHT in the scalp by about 70%.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Finasteride (Propecia / Proscar) vial

DETAILED OVERVIEW

What is Finasteride (Propecia / Proscar)?

Finasteride is a prescription medicine, sold under the brand names Propecia and Proscar. It was originally approved for an enlarged prostate and later also for male pattern hair loss. Steroid-using bodybuilders also use it against the hair loss that gets worse alongside steroid use.

It blocks the enzyme that turns testosterone into DHT (dihydrotestosterone, a strong male hormone), lowering DHT in the scalp by about 70%. Hair loss slows and some hair may grow back, but this takes months. Sexual side effects (lower sex drive, erection and ejaculation problems) are common; they usually go away after stopping, but rare, disputed cases of lasting complaints have been described. The official prescribing information also warns about mood problems (depression, anxiety and, rarely, suicidal thoughts). It must not be used in pregnancy, because it can cause abnormal development of a male baby's genitals. It is not on the anti-doping list.

Mechanism

Blocks the second type of 5α-reductase; about 70% less DHT in the scalp

Half-life

~6 h parent, pharmacodynamic effect 24+ h enzyme inhibition

Onset

DHT reduction measurable 24 h, hair stabilization 3-6 months

Legal status

FDA + EMA Rx, HU + PL approved, WADA allowed (not 5AR-banned)

Data console

Lab data

Androgenic:AnabolicN/A (not AAS, 5AR inhibitor)
AR bindingType-II 5AR Ki ~5 nM (competitive), Type-I 5AR ~100× less…
Active half-life~6 h (parent), but 24+ h enzyme inhibition reversal depends on new synthesis
Detection windowPreviously listed as 5AR masking agent; removed from WADA list 2009 – now allowed.
AromatizationDoes not aromatize – competitive type-II 5α-reductase inhibitor; inhibits DHT conversion, does NOT directly affect the estrogen axis (but secondary E2 elevation may follow testosterone rise).
HepatotoxicityLow – non-steroidal in mechanism but 4-aza-steroid structure. Rare cholestasis case reports (FDA Propecia label). Post-finasteride syndrome (PFS) – controversial neurosteroid-mediated mood/sexual dysfunction long-term sequela ~1-2% incidence (Irwig 2012 PMID 22366892).

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Sexual dysfunction: reduced libido, erectile dysfunction, decreased ejaculate volume (about 2–8%, dose-dependent, most common adverse effect).
  • Post-finasteride syndrome (PFS): sexual, mood and cognitive symptoms persisting even after discontinuation (about 1–2%, neurosteroid-mediated, controversial but growing evidence).
  • Mood disturbance: depression, anxiety, anhedonia, rarely suicidal ideation (FDA label warning).
  • Gynecomastia and breast tenderness: due to the testosterone→estrogen shift from DHT blockade (rare but documented; any new breast lump must be evaluated to rule out breast cancer).
  • Roughly 50% reduction in PSA level: can mask prostate cancer screening, the PSA value requires correction in clinical interpretation.
  • Initial shedding (telogen effluvium): a paradoxical transient increase in hair loss may occur in the first 4–8 weeks of therapy.
  • Rare cholestasis / liver enzyme elevation and hypersensitivity reactions (rash, pruritus, angioedema) reported in isolated cases.

Contraindications · 7

  • Pregnancy and pregnant (or potentially pregnant) partner: Pregnancy Category X – DHT suppression can cause malformation of the fetal male external genitalia. A pregnant woman must NOT handle the tablets (especially broken/crushed ones).
  • Women (of childbearing potential) and children: not indicated; teratogenic risk and no proven benefit.
  • History of depression or other mood disorder: relative contraindication due to increased risk of mood side effects and PFS.
  • Known hypersensitivity to finasteride or other 5α-reductase inhibitors (e.g. dutasteride).
  • Adolescents (<18 years): 5AR blockade during development is not indicated.
  • Severe hepatic impairment: finasteride is metabolized in the liver (CYP3A4), caution / monitoring is required with reduced function.
  • Family history of androgen insensitivity syndrome (AIS) or AR mutation: further reduction of androgen signaling should be avoided.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Finasteride (Propecia / Proscar)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.